Questions swirl after Trump’s GLP-1 pricing deal announcement

At a White House event Thursday, President Trump announced deals with drug makers Novo Nordisk and Eli Lilly to offer their popular GLP-1 obesity and diabetes drugs at lower prices for some Americans, namely some on Medicare and Medicaid plans. But questions linger about the significance of the deal.

According to the announcement, Medicare and state Medicaid programs will be able to purchase a month’s supply of Ozempic, Wegovy, Mounjaro, and Zepbound at $245 each for eligible patients. Eligible people on Medicare will have a $50 co-pay for them.

The negotiated price is a significant cut from the drugs’ list prices: The list price for Ozempic is $997; Wegovy is $1,350; Mounjaro is $1,080; and Zepbound is $1,086. But, of course, purchasers rarely pay drug list prices. It’s unclear how much Medicare and Medicaid would have paid for the drugs without this deal and what the savings will be.

Read full article

Comments

Content Accuracy: Keewee.News provides news, lifestyle, and cultural content for informational purposes only. Some content is generated or assisted by AI and may contain inaccuracies, errors, or omissions. Readers are responsible for verifying the information. Third-Party Content: We aggregate articles, images, and videos from external sources. All rights to third-party content remain with their respective owners. Keewee.News does not claim ownership or responsibility for third-party materials. Affiliate Advertising: Some content may include affiliate links or sponsored placements. We may earn commissions from purchases made through these links, but we do not guarantee product claims. Age Restrictions: Our content is intended for viewers 21 years and older where applicable. Viewer discretion is advised. Limitation of Liability: By using Keewee.News, you agree that we are not liable for any losses, damages, or claims arising from the content, including AI-generated or third-party material. DMCA & Copyright: If you believe your copyrighted work has been used without permission, contact us at dcma@keewee.news. No Mass Arbitration: Users agree that any disputes will not involve mass or class arbitration; all claims must be individual.